Insider activity at C4 Therapeutics, Inc. has been all selling for a year now: about $22,000 from one seller, and zero buyers on the open market.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. 148 investment managers listed CCCC in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | REYNO LEONARD | Executive Officer | Sell | 10,000 | $2.22 | $22K | SEC |
| Feb 18, 2025 | Boyle Scott N | Executive Officer | Sell | 490 | $3.15 | $2K | SEC |
| Feb 18, 2025 | Boyle Scott N | Executive Officer | Sell | 669 | $3.15 | $2K | SEC |
| Feb 10, 2023 | Koppikar Utpal | Director | Buy | 5,667 | $5.60 | $32K | SEC |
In the last 12 months C4 Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $22,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CCCC was filed on 2026-01-16.
148 investment managers reported holding CCCC in SEC Form 13F filings for Q2 2026.
No congressional trades in CCCC were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).